NCT01327781
Z-Endoxifen Hydrochloride in Treating Patients With Metastatic or Locally Recurrent Estrogen Receptor-Positive Breast Cancer
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
The 50 most recent of 131 versions: 4 with changes below, 46 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 55 words
- Study completion pushed from Oct 30, 2026 to Oct 13, 2027
- Secondary endpoints: details revised at 1 of 3 entries
- Study description revised
- Minor Study completion date: Oct 30, 2025 to Oct 30, 2026v94
- Minor Study completion date: Oct 30, 2024 to Oct 30, 2025v91
- Minor Study completion date: Oct 30, 2024v87
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
MTD defined as the highest dose level where at most 1 of 6 patients develops a dose limiting toxicity and 2 or more of the 3-6 patients treated at the next higher dose level develop a dose limiting toxicity
Timeframe: 28 days
Secondary (3)
Progression-free survival
Overall survival
Change in hot flash scores graded using a hot flash diary and the hot flash interference scale
Arms and interventions
Treatment (Z-endoxifen hydrochloride)Experimental
Patients receive Z-endoxifen hydrochloride PO on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Drugs: Endoxifen Hydrochloride
Other: Laboratory Biomarker Analysis, Pharmacological Study, Questionnaire Administration
Sites
3 sites in 1 country